CERUS- MET PRIMARY EFFICACY ENDPOINT DEMONSTRATING NON-INFERIORITY OF INTERCEPT RBCS TO CONVENTIONAL RBCS BY ADJUSTED HEMOGLOBIN INCREMENT

Reuters · 20h ago

Please log in to view news